131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
Completed · Phase 2
Conditions studied: Neuroblastoma
In brief
RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells. PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.
Key facts
- Study ID
- NCT00293319
- Run by
- University of California, San Francisco
- People needed
- 164
- Starts
- 2005-04-01
- Expected to finish
- 2006-03-01
- Last updated by the study team
- 2014-08-18
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.